PIERDOMENICO, MARIA
 Distribuzione geografica
Continente #
NA - Nord America 884
EU - Europa 165
AS - Asia 85
Continente sconosciuto - Info sul continente non disponibili 1
SA - Sud America 1
Totale 1.136
Nazione #
US - Stati Uniti d'America 869
IT - Italia 76
CN - Cina 39
IN - India 30
SE - Svezia 27
FI - Finlandia 16
DE - Germania 14
CA - Canada 10
UA - Ucraina 9
SG - Singapore 7
TR - Turchia 7
GB - Regno Unito 5
BZ - Belize 4
IE - Irlanda 4
RO - Romania 4
BE - Belgio 3
BG - Bulgaria 3
JP - Giappone 2
CL - Cile 1
EU - Europa 1
GR - Grecia 1
HU - Ungheria 1
MX - Messico 1
NL - Olanda 1
PT - Portogallo 1
Totale 1.136
Città #
Fairfield 154
Chandler 83
Seattle 78
Woodbridge 76
Ashburn 59
Wilmington 58
Cambridge 56
Houston 53
Rome 35
Beijing 24
San Paolo di Civitate 23
Princeton 20
Plano 16
Lawrence 15
Ann Arbor 14
San Jose 13
Millbury 12
New York 8
San Diego 8
Boston 7
Istanbul 7
Ottawa 7
Andover 6
Norwalk 6
Las Vegas 5
Belize City 4
Dublin 4
Los Angeles 4
Nanjing 4
Saint Louis 4
San Pietro in Cariano 4
Singapore 4
Bollate 3
Brussels 3
Buffalo 3
Hefei 3
Iasi 3
Albuquerque 2
Baotou 2
Columbus 2
Fremont 2
Helsinki 2
Jacksonville 2
Kunming 2
Milan 2
Montréal 2
Redwood City 2
Southend 2
Absecon 1
Aigaleo 1
Altopascio 1
Bremen 1
Capranica 1
Chicago 1
Dearborn 1
Decatur 1
Falls Church 1
Florence 1
Grafing 1
Guangzhou 1
Indiana 1
Lido 1
Mainz 1
Mazzano Romano 1
Mexico City 1
Nürnberg 1
Omegna 1
Phoenix 1
Provo 1
Pune 1
Redmond 1
Salerno 1
Sant'antimo 1
Shenyang 1
Sofia 1
Toronto 1
Totale 936
Nome #
RIP3 AND pMLKL promote necroptosis-induced inflammation and alter membrane permeability in intestinal epithelial cells 107
The Identification and Pharmacological Characterization of 6-(tert-Butylsulfonyl)-N-(5-fluoro-1H-indazol-3-yl)quinolin-4-amine (GSK583), a Highly Potent and Selective Inhibitor of RIP2 Kinase 91
Role of HMGB1 as a suitable biomarker of subclinical intestinal inflammation and mucosal healing in patients with inflammatory bowel disease 89
Dipotassium glycyrrhizate via HMGB1 or AMPK signaling suppresses oxidative stress during intestinal inflammation 88
NOD2 Is Regulated by MIR-320 in Physiological Conditions but this Control Is Altered in Inflamed Tissues of Patients with Inflammatory Bowel Disease 86
Necroptosis Is Active in Children With Inflammatory Bowel Disease and Contributes to Heighten Intestinal Inflammation 79
NOD2 and inflammation: current insights 77
Fecal HMGB1 Is a Novel Marker of Intestinal Mucosal Inflammation in Pediatric Inflammatory Bowel Disease 76
New Insights Into the Pathogenesis of Inflammatory Bowel Disease: Transcription Factors Analysis in Bioptic Tissues From Pediatric Patients 75
Characterization of adherent-invasive Escherichia coli isolated from pediatric patients with inflammatory bowel disease 74
NOD2 induces autophagy to control AIEC bacteria infectiveness in intestinal epithelial cells 73
Presenting features and disease course of pediatric ulcerative colitis. 69
Altered expression of innate immunity genes in different intestinal sites of children with ulcerative colitis 68
Validating the Role of Necroptosis in Inflammatory Bowel Disease (IBD) Pathogenesis 66
Mapping histologic patchiness of celiac disease by push enteroscopy 58
Activated Rip2 kinase is overexpressed in the intestinal mucosa of adult and pediatric inflammatory bowel disease patients and may represent a novel therapeutic target. 46
Totale 1.222
Categoria #
all - tutte 2.570
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.570


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019157 0 0 0 0 0 0 0 0 0 37 68 52
2019/2020310 36 10 2 15 30 30 51 43 36 28 14 15
2020/2021141 25 11 0 3 6 8 4 6 18 33 12 15
2021/2022198 0 4 35 1 19 13 5 16 14 15 32 44
2022/2023238 40 65 18 25 21 15 4 16 21 5 5 3
2023/202473 3 13 0 6 10 13 1 14 0 13 0 0
Totale 1.222